• There are no suggestions because the search field is empty.

Why a Strong Quality System Is Critical for Pharmacovigilance Success

person-image
Almudena Soriano, Senior Consultant Drug Safety at QbD Group

Discover why a strong quality system is essential for effective pharmacovigilance. Learn how it ensures compliance, safety, and continuous improvement.

Quality Systems in Pharmacovigilance: Why They Matter | QbD Group
3:46

Ensuring the safety of authorised medicines doesn’t happen by accident. It takes a well-structured system with clearly defined responsibilities, trained professionals, and a robust quality framework. That’s why a solid quality system is at the heart of any effective pharmacovigilance (PV) strategy.

In this blog post, we explore the essential components of a PV quality system and explain how it supports compliance, safety, and continuous improvement.

Why quality matters in pharmacovigilance

According to Module I of the Good Pharmacovigilance Practice (GVP), a pharmacovigilance system is designed to fulfil statutory PV responsibilities and monitor the safety of medicinal products on the market. The ultimate goal? Detect changes in the benefit-risk profile and ensure that the benefits of a medicine continue to outweigh the risks.

But reaching this goal requires more than monitoring safety data. It demands a strong, fit-for-purpose quality system that:

 

  • Ensures compliance with pharmacovigilance legislation
  • Minimises risk of harm from adverse reactions
  • Promotes safe and effective use of medicines
  • Supports public health through timely safety communication

Core elements of a pharmacovigilance quality system

A good quality system is more than a set of procedures—it’s a tool for prevention, continuous improvement, and accountability. Some key components include:

 

1. Trained and qualified personnel

Pharmacovigilance responsibilities must be carried out by people with the right skills and knowledge. That’s why every PV team should have a training plan tailored to the specific needs of the organisation. This ensures consistent performance and up-to-date expertise.

2. Performance monitoring and continuous improvement

How do you know your PV system is working? By monitoring it. Quality indicators should be defined and tracked regularly. In addition, planned audits help assess whether the PV system meets its goals and where improvements can be made.

3. Comprehensive documentation

Traceability is key. All activities, processes, and results must be clearly documented—not just for compliance, but to provide evidence of consistent performance and support data-driven decisions.

4. Standardised procedures

Every activity must be described in procedures and work instructions to ensure it is always performed in the same way, regardless of who is executing it. This helps reduce variation and prevents errors.

5. Risk-based continuity planning

Interruptions in PV activities can have serious consequences. Risk-based business continuity plans help ensure critical pharmacovigilance tasks continue even during disruptions.

Together, these elements ensure that PV systems are not only compliant, but also resilient, transparent, and continuously improving.

Quality drives safety and trust

Working with medicinal products carries a high level of responsibility. The quality of your processes directly impacts the safety of patients and the public. That’s why designing and maintaining a solid quality system is not just a regulatory obligation; it’s a commitment to patient protection.

How QbD Group can support you

At QbD Group, we believe that quality systems are the foundation of good pharmacovigilance. We not only maintain our own high standards internally, but we also support our clients in building, optimizing, and maintaining their PV systems to meet regulatory and operational expectations.

Need help with setting up or improving your pharmacovigilance quality system? Let’s talk about how we can support your PV quality system, whether you’re starting from scratch or refining an existing one.

Contact QbD Group today.

 

 

 

Stay ahead in life sciences

Keeping up with the fast-paced life sciences industry doesn’t have to be overwhelming.

Our newsletter delivers the latest insights, industry updates, and expert content directly to your inbox, helping you stay informed and make smarter decisions.

Circles-banner-short

Discover more expert content

preview_image
Blog

MDSW for Startups: A Practical Guide to Compliant Medical Software Development

Medical Device Software (MDSW) development can feel like a regulatory...
preview_image
Blog

Bridging the Regulatory Gap: Integrating IVDs into Global Clinical Trials

As global clinical trials grow in scale and complexity, integrating...
preview_image
Blog

IVD Use in EU Clinical Trials: Key Considerations Under the IVDR

The use of in vitro diagnostic (IVD) devices in clinical trials has...
preview_image
Blog

Toxicological Assessment of Extractables and Leachables (E&L)

Ensuring the safety and efficacy of pharmaceutical products involves more...
preview_image
Blog

Scale Smart: Choosing the Right Pharmacovigilance Operating Model for EU Growth

Scaling pharmacovigilance (PV) across Europe is as much an organizational...
preview_image
Blog

Update manual on borderline classification IVDR and MDR published

The revision includes clarifications for borderline cases, including red blood...
preview_image
Blog

Revised Team NB Position Paper on Best Practices for Submission of Technical Documentation under IVDR

The revision includes updates to various sections and brings the content...
preview_image
Blog

Adoption of Commission Delegated Regulation (EU) 2025/788 amending Delegated Regulation (EU) 2023/2197 as regards the date of application and new revision of MDCG 2024-14

The amendment defers the application of the rules on the assignment of Unique...
preview_image
Blog

New MDCG position paper released on the timelines of implementation of Master UDI-DI to contact lenses and spectacle frames, spectacle lenses and ready-to-wear reading spectacles

The paper explains how the Master UDI-DI solution, introduced through recent...
preview_image
Blog

Adoption of Decision 2025/1324 on expert panels in the field of medical devices

The new panel can provide scientific and clinical advice for devices intended...